14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
Seyfarth Synopsis: The Illinois Supreme Court recently affirmed a state appellate court’s holding ...
Read More >
A Hollywood union’s recent amendments to its union rules has sparked federal antitrust lawsuits by ...
Read More >
Welcome to the June edition of the Alston & Bird CPSC Recall Snapshot. In May, the CPSC held its pu...
Read More >
The trend toward limiting U.S. federal income tax benefits associated with public company executive ...
Read More >
Biometric information is unique to each of us, including our fingerprints, voice, face, iris, and DN...
Read More >
In this episode I visit with podcast favorite Jim Murphy, who is the VP of Products at Hanzo. We dis...
Read More >